Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues
Rhea-AI Filing Summary
Immuron Limited filed a Form 6-K to furnish results of its 2026 Extraordinary General Meeting. Shareholders passed all resolutions in the Notice of Meeting by poll.
Two ordinary resolutions ratifying prior issues of shares under ASX Listing Rules 7.1 and 7.1A were carried, with poll votes of 63.95% for and 36.05% against on each resolution.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February 2026
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published an announcement (the “Public Notices”) to the Australian Securities Exchange on February 12, 2026, titled:
| 99.1 | Results of meeting |
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
1
EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Results of meeting |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMURON LIMITED | ||
| Date: February 12, 2026 | By: | /s/ Olga Smejkalova |
| Olga Smejkalova | ||
| Company Secretary | ||
3
Exhibit 99.1
ASX/NASDAQ Announcement
12 February 2026
2026 Extraordinary General Meeting Results
In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the Company) advises that the shareholders of the Company passed all resolutions in the Notice of Meeting at the 2026 Extraordinary General Meeting held earlier today.
All resolutions put to the meeting were carried by way of a poll. All resolutions were carried. Details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.
- - - END - - -
This release has been authorised by the Directors of Immuron Limited.
Further information
Steven Lydeamore
Chief Executive Officer
steve@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
Immuron Platform Technology
Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper- immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.
For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Sign up to Immuron’s Investor Hub: Here
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
2
Immuron Limited
General Meeting
Thursday, 12 February 2026
Results of Meeting
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
| Resolution details | Instructions
given to validly appointed proxies (as at proxy close) |
Number
of votes cast on the poll (where applicable) |
Resolution
Result |
If s250U | ||||||
| applies | ||||||||||
| Resolution | Resolution Type | For | Against | Proxy’s Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried | |
| 1. Ratification of prior issue of shares – Listing Rule 7.1 | Ordinary | 12,210,847 57.11% | 7,942,172 37.15% | 1,226,929 5.74% | 53,800 | 14,090,685 63.95% | 7,942,172 36.05% | 53,800 | Carried | NA |
| 2. Ratification of prior issue of shares – Listing Rule 7.1A | Ordinary | 12,210,847 57.11% | 7,942,172 37.15% | 1,226,929 5.74% | 53,800 | 14,090,685 63.95% | 7,942,172 36.05% | 53,800 | Carried | NA |
| * | Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll. |
3
FAQ
What did Immuron Limited (IMRN) report in its February 2026 Form 6-K?
What was the key outcome of Immuron Limited’s 2026 Extraordinary General Meeting?
Why did Immuron Limited (IMRN) reference ASX Listing Rules 7.1 and 7.1A?
Did any resolutions fail at Immuron Limited’s 2026 Extraordinary General Meeting?
Filing Exhibits & Attachments
3 documents